X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs AUROBINDO PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA AUROBINDO PHARMA CIPLA/
AUROBINDO PHARMA
 
P/E (TTM) x 44.2 15.6 283.7% View Chart
P/BV x 3.9 4.0 96.4% View Chart
Dividend Yield % 0.3 0.4 85.3%  

Financials

 CIPLA   AUROBINDO PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
AUROBINDO PHARMA
Mar-17
CIPLA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs622895 69.5%   
Low Rs458622 73.7%   
Sales per share (Unadj.) Rs181.9254.6 71.4%  
Earnings per share (Unadj.) Rs12.939.3 32.8%  
Cash flow per share (Unadj.) Rs29.346.6 62.9%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.40.3 112.3%  
Book value per share (Unadj.) Rs155.7160.0 97.3%  
Shares outstanding (eoy) m804.51585.88 137.3%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.03.0 99.7%   
Avg P/E ratio x42.019.3 217.3%  
P/CF ratio (eoy) x18.416.3 113.1%  
Price / Book Value ratio x3.54.7 73.2%  
Dividend payout %15.56.4 244.1%   
Avg Mkt Cap Rs m434,516444,390 97.8%   
No. of employees `00023.014.0 164.8%   
Total wages/salary Rs m26,33817,678 149.0%   
Avg. sales/employee Rs Th6,349.110,667.8 59.5%   
Avg. wages/employee Rs Th1,143.01,264.3 90.4%   
Avg. net profit/employee Rs Th449.31,645.8 27.3%   
INCOME DATA
Net Sales Rs m146,302149,157 98.1%  
Other income Rs m2,2871,159 197.3%   
Total revenues Rs m148,589150,316 98.9%   
Gross profit Rs m24,75834,343 72.1%  
Depreciation Rs m13,2294,276 309.4%   
Interest Rs m1,594667 238.9%   
Profit before tax Rs m12,22230,558 40.0%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7987,597 23.7%   
Profit after tax Rs m10,35423,012 45.0%  
Gross profit margin %16.923.0 73.5%  
Effective tax rate %14.724.9 59.2%   
Net profit margin %7.115.4 45.9%  
BALANCE SHEET DATA
Current assets Rs m87,37092,062 94.9%   
Current liabilities Rs m33,08166,223 50.0%   
Net working cap to sales %37.117.3 214.2%  
Current ratio x2.61.4 190.0%  
Inventory Days Days87106 82.1%  
Debtors Days Days6268 92.1%  
Net fixed assets Rs m111,56762,919 177.3%   
Share capital Rs m1,609586 274.6%   
"Free" reserves Rs m123,64593,133 132.8%   
Net worth Rs m125,25493,719 133.6%   
Long term debt Rs m36,4541,814 2,009.6%   
Total assets Rs m209,532162,494 128.9%  
Interest coverage x8.746.8 18.5%   
Debt to equity ratio x0.30 1,503.6%  
Sales to assets ratio x0.70.9 76.1%   
Return on assets %5.714.6 39.1%  
Return on equity %8.324.6 33.7%  
Return on capital %8.532.7 26.0%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,06675,838 67.3%   
Fx outflow Rs m17,67830,224 58.5%   
Net fx Rs m33,38845,613 73.2%   
CASH FLOW
From Operations Rs m23,82432,786 72.7%  
From Investments Rs m-13,127-17,870 73.5%  
From Financial Activity Rs m-13,239-19,153 69.1%  
Net Cashflow Rs m-2,478-4,239 58.5%  

Share Holding

Indian Promoters % 16.0 54.1 29.6%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 8.0 153.5%  
FIIs % 23.7 27.7 85.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.2 256.9%  
Shareholders   161,166 69,601 231.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  DR. DATSONS LABS  AJANTA PHARMA  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 22, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS